Resapp Health Azione

Resapp Health Conversione FCF

Il Tasso di Conversione FCF (FCF/EBITDA) di Resapp Health (RAP.AX) al 12 ago 2026 è 58,85 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 84,29 % — una variazione del -30,18% (inferiore).

Conversione FCF

58,85 %

YoY

-30,18%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Resapp Health ammonta a 2026 58,85 % . Tasso di Conversione FCF (FCF/EBITDA) di Resapp Health ammontava a 2025 84,29 % . Diminuisce del -30,18% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Resapp Health Analisi delle Azioni

Cosa fa Resapp Health? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Resapp Health azioni

Tasso di Conversione FCF (FCF/EBITDA) di Resapp Health è 58,85 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di Resapp Health è passato da 84,29 % a 58,85 %, con una variazione del -30,18 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Resapp Health di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Resapp Health di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — Resapp Health

Tutte le Metriche Finanziarie — Resapp Health